XBiotech’s Ebola program was initiated in response to the recent devastating Ebola outbreak and we have since established a Cooperative Research and Development Agreement (CRADA) with the United States Military Research Institute for Infectious Diseases (USAMRIID). The aggressive timeline for the development of a therapy for Ebola once again demonstrates that the True Human™ platform enables a rapid transition from discovery to breakthrough therapy:

  • January/February 2015: Received blood from Ebola-recovered patients
  • May 2015: Identified and cloned first True Human™ anti-Ebola antibodies
  • August 2015: Established Cooperative Research and Development Agreement (CRADA) with USAMRIID
  • November 2015: USAMRIID Reported 8 out of 10 XBiotech antibodies effectively neutralized a deadly strain of Ebola virus from a recent outbreak in Africa